Project Grant 00000TO03280005

The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $426,746 on September 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate innovative methods for improving tuberculosis detection, prevention, and treatment among migrant communities in New York City. Columbia's Health Sciences Division will implement the SPOT-TB intervention (Screening with Portable X-rays for Rapid Recognition...

The National Heart Lung and Blood Institute awarded The Regents of the University of California, San Francisco $1,265,657 on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a two-stage randomized trial evaluating optimal tuberculosis screening and preventive therapy delivery strategies for pregnant women with HIV in Uganda. The study uses a sequential, multiple assignment, randomized trial design to determine whether C-reactive protein screening...

The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, San Francisco $358,032 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a systematic evaluation of post-tuberculosis lung disease (PTLD) and its relationship to HIV status. The project, titled "The Sequelae TB Study," will comprehensively characterize PTLD among a prospective cohort of TB survivors in Lusaka, Zambia. The...

The National Institute of Allergy and Infectious Diseases awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $2.060 million on September 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host-bacterial interactions determining the spectrum of Mycobacterium tuberculosis transmission. The research examines the biology of MTB infection across exposed household contacts and "resister"...

The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital $685,682 on September 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the use of chest radiography in detecting early tuberculosis in children and youth. The research evaluates whether chest radiography abnormalities identified during community-based TB screening can predict subsequent active TB disease in young individuals, with the goal of...

The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $795,622 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mycobacterium tuberculosis impact on HIV reservoir clearance. The research examines how tuberculosis disease affects HIV-1 latent reservoirs in people living with HIV. The study will recruit 200 people with HIV, half with active tuberculosis disease, and follow them for up to 18 months....

The National Institute of Allergy and Infectious Diseases awarded Emory University $2.347 million on September 16, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infectiousness and social mixing patterns in asymptomatic tuberculosis as a driver of population-level transmission. The research examines when individuals with asymptomatic TB become infectious and where they encounter susceptible populations in community settings. The project...

The National Institute of Allergy and Infectious Diseases awarded Trudeau Institute Inc. $332,414 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the mechanism of action of tuberculocidal compound TI-507 and validate NAD kinase (PPNK) as a novel therapeutic target in Mycobacterium tuberculosis. TI-507, initially identified as a human sphingosine kinase inhibitor, demonstrates activity against MTB with an IC50 of 22 mM, kills persister...

The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Washington $1,343,164 on July 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into asymptomatic tuberculosis transmission, infectiousness, and immunology conducted in Nairobi, Kenya. The research investigates the infectiousness spectrum of asymptomatic TB, identifies risk factors for increased...

The National Institute of Allergy and Infectious Diseases awarded Rutgers The State University of New Jersey $8.74 million on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish and operate a consortium supporting rigorous evaluation and development of early-stage tuberculosis diagnostics, including drug susceptibility tests. The award funds a fast-paced pipeline combining technology scouting, development mentoring, and clinical testing of TB...